Treating Psoriatic Arthritis to Target: Defining the Psoriatic Arthritis Disease Activity Score That Reflects a State of Minimal Disease Activity

REFERENCES

1. 1.↵
   1. Gladman DD,
   2. Shuckett R,
   3. Russell ML,
   4. Thorne JC,
   5. Schachter RK

   . Psoriatic arthritis (PsA)—an analysis of 220 patients. Q J Med 1987;62:127–41.

   OpenUrlPubMed
2. 2.↵
   1. Rosen CF,
   2. Mussani F,
   3. Chandran V,
   4. Eder L,
   5. Thavaneswaran A,
   6. Gladman DD

   . Patients with psoriatic arthritis have worse quality of life than those with psoriasis alone. Rheumatology 2012;51:571–6.

   OpenUrlCrossRefPubMed
3. 3.↵
   1. Taylor WJ,
   2. Mease PJ,
   3. Adebajo A,
   4. Nash PJ,
   5. Feletar M,
   6. Gladman DD

   . Effect of psoriatic arthritis according to the affected categories of the international classification of functioning, disability and health. J Rheumatol 2010;37:1885–91.

   OpenUrlAbstract/FREE Full Text
4. 4.↵
   1. Rajendran CP,
   2. Ledge SG,
   3. Rani KP,
   4. Madhavan R

   . Psoriatic arthritis. J Assoc Physicians India 2003;51:1065–8.

   OpenUrlPubMed
5. 5.↵
   1. Wong PC,
   2. Leung YY,
   3. Li EK,
   4. Tam LS

   . Measuring disease activity in psoriatic arthritis. Int J Rheumatol 2012;2012:839425.

   OpenUrlPubMed
6. 6.↵
   1. Mumtaz A,
   2. Gaallagher P,
   3. Kirby B,
   4. Waxman R,
   5. Coates L,
   6. Douglas J,
   7. et al.

   Development of a preliminary composite disease activity index in psoriatic arthritis. Ann Rheum Dis 2011;70:272–7.

   OpenUrlAbstract/FREE Full Text
7. 7.↵
   1. Coates LC,
   2. FitzGerald O,
   3. Mease PJ,
   4. Gladman DD,
   5. Strand V,
   6. Goel N,
   7. et al.

   Development of a disease activity and responder index for psoriatic arthritis—report of the Psoriatic Arthritis Module at OMERACT 11. J Rheumatol 2014;41:782–91.

   OpenUrlAbstract/FREE Full Text
8. 8.↵
   1. Cauli A,
   2. Gladman DD,
   3. Mathieu A,
   4. Olivieri I,
   5. Porru G,
   6. Tak PP,
   7. et al;
   8. GRAPPA 3PPsA Study Group

   . Patient global assessment in psoriatic arthritis: a multicenter GRAPPA and OMERACT study. J Rheumatol 2011;38:898–903.

   OpenUrlAbstract/FREE Full Text
9. 9.↵
   1. Schoels M,
   2. Aletaha D,
   3. Funovits J,
   4. Kavanaugh A,
   5. Baker D,
   6. Smolen JS

   . Application of the DAREA/DAPSA score for assessment of disease activity in psoriatic arthritis. Ann Rheum Dis 2010;69:1441–7.

   OpenUrlAbstract/FREE Full Text
10. 10.↵
    1. Helliwell PS,
    2. FitzGerald O,
    3. Fransen J,
    4. Gladman DD,
    5. Kreuger GG,
    6. Callis-Duffin K,
    7. et al.

    The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). Ann Rheum Dis 2013;72:986–91.

    OpenUrlAbstract/FREE Full Text
11. 11.↵
    1. Helliwell PS,
    2. Coates LC

    . The definition of remission in psoriatic arthritis: can this be accurate without assessment of multiple domains? Ann Rheum Dis 2015;74:e66.

    OpenUrlFREE Full Text
12. 12.↵
    1. Coates LC,
    2. FitzGerald O,
    3. Merola JF,
    4. Smolen J,
    5. van Mens LJ,
    6. Bertheussen H,
    7. et al.

    Group for Research and Assessment of Psoriasis and Psoriatic Arthritis/Outcome Measures in Rheumatology consensus-based recommendations and research agenda for use of composite measures and treatment targets in psoriatic arthritis. Arthritis Rheumatol 2018;70:345–55.

    OpenUrl
13. 13.↵
    1. Helliwell PS,
    2. Kavanaugh A

    . Comparison of composite measures of disease activity in psoriatic arthritis using data from an interventional study with golimumab. Arthritis Care Res 2014;66:749–56.

    OpenUrl
14. 14.↵
    1. Helliwell PS,
    2. Kavanaugh A

    . Radiographic progression is less in psoriatic arthritis achieving a good response to treatment: data using newer composite indices of disease activity. Arthritis Care Res 2018;70:797–800.

    OpenUrl
15. 15.↵
    1. Helliwell P,
    2. FitzGerald O,
    3. Fransen J

    . Composite disease activity and responder indices for psoriatic arthritis: A report from the GRAPPA 2013 meeting on development of cutoffs for both disease activity states and response. J Rheumatol 2014;41:1212–7.

    OpenUrlAbstract/FREE Full Text
16. 16.↵
    1. Coates LC,
    2. Fransen J,
    3. Helliwell PS

    . Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis 2010;69:8–53.

    OpenUrl
17. 17.↵
    1. Coates LC,
    2. Cook R,
    3. Lee KA,
    4. Chandran V,
    5. Gladman DD

    . Frequency, predictors, and prognosis of sustained minimal disease activity in an observational psoriatic arthritis cohort. Arthritis Care Res 2010;62:970–6.

    OpenUrlCrossRef
18. 18.↵
    1. Coates LC,
    2. Helliwell PS

    . Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data. Arthritis Care Res 2010;62:965–9.

    OpenUrlCrossRef
19. 19.↵
    1. Coates LC,
    2. Helliwell PS

    . Defining low disease activity states in psoriatic arthritis using novel composite disease instruments. J Rheumatol 2016;43:371–5.

    OpenUrlAbstract/FREE Full Text
20. 20.↵
    1. Hajian-Tilaki K

    . Receiver operating characteristic (ROC) curve analysis for medical diagnostic test evaluation. Caspian J Intern Med 2013;4:627–35.

    OpenUrlPubMed
21. 21.↵
    1. Coates LC,
    2. Moverley AR,
    3. McParland L,
    4. Brown S,
    5. Navarro-Coy N,
    6. O’Dwyer JL,
    7. et al.

    Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomized controlled trial. Lancet 2015;386:2489–98.

    OpenUrlCrossRefPubMed
22. 22.↵
    1. Sheane BJ,
    2. Thavaneswaran A,
    3. Gladman DD,
    4. Chandran V

    . Attainment of minimal disease activity using methotrexate in psoriatic arthritis. J Rheumatol 2016;43:1718–23.

    OpenUrlAbstract/FREE Full Text